In this context, an intermittent schedule of high doses of lapatinib was shown by Moasser and colleagues to be effective at blocking HER2/HER3 signaling and consequently triggering apoptosis in HER2+ tumor cell lines and breast cancer xenografts [34]. The gene discussed is ERBB3; the disease is breast carcinoma.